Indegene Ltd
Indegene Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY27 is anticipated as a year of scaling FY26 strategies, with doubling or tripling down on customer engagement, revenue, and internal efficiencies. FY27 is expected to be a year of scaling FY26 initiatives, focusing on customer engagement, revenue growth, and internal efficiencies.
From Indegene Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 is anticipated as a year of scaling FY26 strategies, with doubling or tripling down on customer engagement, revenue, and internal efficiencies.
- Strong pipeline entering FY27, larger and more balanced across top 20 and beyond top 20 customers, with outside top 20 segment growing faster.
- Continued traction in GenAI-led solution wins across customer segments and business lines driving growth.
- Tectonic transformation model expected to become a material revenue driver, with multi-region expansion underway from initial wins in Germany.
- Expansion into mid-sized and small biotech companies highlighted as a high-growth opportunity with integrated commercial models.
2 more points from Indegene Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indegene Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indegene continues to invest in AI and technology, notably through its "Transform AI" program targeting increased revenue per employee and new revenue pools.
- Investments include R&D expenses slightly above 2% of revenues, GTM (go-to-market) investments, and domain expertise enhancement to support customer handholding during transformation.
- The company made three acquisitions in FY26—BioPharm, Warn, and Cake Communications—strengthening omnichannel, data targeting capabilities, and local market expertise in Europe to expand global delivery and credibility.
- They are scaling their Tectonic transformation model, combining GenAI with creative expertise, already securing multiple customers and expected to be a material growth driver in FY27.
- Indegene is investing in category-defining AI-enabled platforms like Cortex, Content Super App, and Medical Writing Platform, deployed to transform workflows.
2 more points from Indegene Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indegene Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the exact current or expected order book value or pending orders in numeric terms.
- However, strong deal activity and a robust pipeline are highlighted, with several large wins:
- Multiple $1 million-plus deals were closed in Q4, including one $3 million-plus deal in the clinical business.
- A multiyear omnichannel deal exceeding $10 million in ACV was signed in Q3, expected to convert to revenue in H2 FY27.
- The largest customer signed a significant Tectonic engagement starting with Germany, with potential expansion to additional markets.
2 more points from Indegene Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Indegene Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹80 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indegene Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Invicta Diagnostic Ltd (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnos.'s Q4 FY26 earnings…
- KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Gaudium IVF and Women Health Ltd (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
- Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
Arthneeti Pro · Annual
Indegene Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indegene Ltd Q4 FY26 results?
FY27 is anticipated as a year of scaling FY26 strategies, with doubling or tripling down on customer engagement, revenue, and internal efficiencies. FY27 is expected to be a year of scaling FY26 initiatives, focusing on customer engagement, revenue growth, and internal efficiencies.
What is Indegene Ltd share price analysis?
Indegene Ltd currently shows a neutral. The stock trades at a P/E of 31.3 with a market cap of ₹13,016 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indegene Ltd planning capital expenditure?
Indegene continues to invest in AI and technology, notably through its "Transform AI" program targeting increased revenue per employee and new revenue pools.
Keep Indegene Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.